For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can delay the disease.
An open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial Randall J Bateman, Yan Li, Eric M McDade, Jorge J Llibre-Guerra, David B Clifford, Alireza Atri, Susan L Mills, Anna M Santacruz, Guoqiao Wang,Charlene Supnet, Tammie L S Benzinger, Brian A Gordon, Laura Ibanez, Gregory Klein, Monika Baudler, Rachelle S Doody, […]
Clinical trial of people destined to develop early-onset Alzheimer’s disease shows eliminating amyloid from brain may prevent symptoms, supports need for confirmatory studies
Research announced today is the first of its kind to suggest that anti-amyloid drugs can delay or even stop the progression of symptoms in people with early-onset Alzheimer’s.
Study offers clues to treatment, prevention
Haiyan Liu, Thomas W Marsh, Xinyu Shi, Alan E Renton, Kevin M Bowling, Ellen Ziegemeier, Guoqiao Wang, Yuchen Cao, Alisha Aristel, Jessie Li, Alexa Dickson, Richard J Perrin, Alison M Goate, Victoria Fernández, Gregory S Day, Michelle Doering, Alisha Daniels, Brian A Gordon, Tammie L S Benzinger, Jason Hassenstab, Laura Ibanez, Charlene Supnet-Bell, Chengjie Xiong, Ricardo Allegri, Sarah B Berman, Nick C Fox, Natalie Ryan, Edward D Huey, Jonathan Vöglein, James M Noble, Jee Hoon Roh, Mathias Jucker, Christoph Laske, Takeshi Ikeuchi, Raquel Sanchez-Valle, Peter R Schofield, Patricio Chrem Mendez, Jasmeer P […]
Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer’s.
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms arise
